Abstract:Objective An open study was carried out to evaluate the effect of 2 year of zoledronic acid and tibolone treatment on bone mineral density(BMD),bone remodeling markers,and the risk of fracture in women with postmenopausal osteoporosis(PMOP).Methods In total,567 PMOP women,whose ages ranged 55-64 years,were randomized to 3 groups.185 patients received infusion zoledronic acid 5 mg/year,190 patients received oral tibolone 2.5 mg/d and the rest received oral caltrate and calcitriol (control group,n =192).All of them received oral caltrate 600 mg/d and calcitriol 0.25 μg/day.BMD measurements at the lumbar spine and femoral neck by dual-energy X-ray absorptiometry (DEXA) and the biochemical markers of bone metabolism in serum were performed at the baseline and 6,12,and 24 months.Results Comparing baseline with 24 month's values,BMD increased in zoledronic acid and tibolone group,especially lumbar vertebra (L2-4,P＜ 0.01).But there was no significant deference between zoledronic acid and tibolone group (P ＞ 0.05).Zoledronic acid and tibolone resulted in a significantly greater reduction in bone-specific alkaline phosphatase (BALP),osteocalcin,tartrate-resistant acid phosphatase (TRACP5b),and collagen type Ⅰ C-end peptides (CTX) from baseline all post-baseline time (P＜0.01).There was a significant deference between zoledronic acid and tibolone group in TRACP-5b and CTX(P＜0.05).Treatment with zoledronic acid reduced the risk of new vertebral fracture by 61.9％ during a 2-year period,as compared with placebo (4.3％ in the zoledronic-acid group vs 12.6％ in the control group,P=0.033) and reduced the risk of total fracture by 65.9％ (4.3％ in the zoledronic-acid group,12.6％ in the control group,P =0.004).And in Tibolone group,incidence of total fracture were,significantly lower than in the control group (6.5％ vs 12.6％,P =0.047).There was no serious adverse event occurrence in all patientsm.Conclusions Zoledronic acid could significantly improve BMD and reduce the risk of bone fracture as tibolone.Thus it played an important role in the treatment of postmenopausal osteoporosis.There was no significant difference between these two drugs.Zoledronate can improve the compliance and safety of the patients.However,calcium tablet and vitamin D alone could not prevent the loss of bone.

The Beneficial Effects of Bisphosphonate-enoxacin on Cortical Bone Mass and Strength in Ovariectomized Rats

Bisphosphonate‐enoxacin Inhibit Osteoclast Formation and Function by Abrogating RANKL‐induced JNK Signalling Pathways During Osteoporosis Treatment

Bis‑enoxacin Blocks Alveolar Bone Resorption in Rats with Ovariectomy‑induced Osteoporosis

Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.

Evaluation of preventive effect of drug intervention on osteoporosis in ovariectomized rats.

The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats.

Effects of local delivery of BMP2, zoledronate and their combination on bone microarchitecture, biomechanics and bone turnover in osteoporotic rabbits

Efficacy of bisacurone in bone fracture healing process: An experimental study on osteoporotic rats

Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats

Studies on Effects of Biological Calcium Carbonate on Osteoporosis in Ovariectomized Rats

The Effect of Local Injection of Zoledronic Acid and Rhbmp-2 on the Serum Biochemical Index and Trabecular Growth Rate in Rabbit Osteoporosis Model

Oleanolic acid exerts an osteoprotective effect in ovariectomy-induced osteoporotic rats and stimulates the osteoblastic differentiation of bone mesenchymal stem cells in vitro.

Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis

Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-Ct Scanning

The effects of bisphosphonate on the remodeling of different irregular bones in mice.

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats

Efficacy and safety of zoledronic acid in the treatment of osteoporosis: A meta-analysis of randomized controlled trials

Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.

Effect of bisphosphonate on bone microstructure, mechanical strength in osteoporotic rats by ovariectomy

Effects of zoledronic acid and tibolone on bone mineral density, indexes of bone metabolism, and the risk of fracture in patients with postmenopausal osteoporosis

Treatment of osteoporosis with zoledronate and pravastatin in rats